[go: up one dir, main page]

MX2009013355A - Compuesto de piridona. - Google Patents

Compuesto de piridona.

Info

Publication number
MX2009013355A
MX2009013355A MX2009013355A MX2009013355A MX2009013355A MX 2009013355 A MX2009013355 A MX 2009013355A MX 2009013355 A MX2009013355 A MX 2009013355A MX 2009013355 A MX2009013355 A MX 2009013355A MX 2009013355 A MX2009013355 A MX 2009013355A
Authority
MX
Mexico
Prior art keywords
good
receptor agonist
group
pyridone
compound
Prior art date
Application number
MX2009013355A
Other languages
English (en)
Inventor
Takao Okuda
Fukushi Hirayama
Takashi Kamikubo
Masanori Miura
Yuriko Komiya
Keisuke Maki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2009013355A publication Critical patent/MX2009013355A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se hace un estudio intensivo y extensivo sobre un agonista del receptor EP4, y se encuentra que un nuevo compuesto de piridona en el cual la posición 1 de un anillo piridona está sustituida por un grupo que tiene un grupo ácido tal como un grupo carboxilo, y la posición 6 del anillo piridona está unida a un grupo anillo aromático por medio de un alquilo inferior, un alquileno inferior, un éter o un tioéter, tiene una buena actividad agonista del receptor EP4. El compuesto tiene una buena actividad agonista del receptor EP4 y una buena actividad de aumentar el flujo de sangre femoral en una rata, y por lo tanto es útil como un agente medicinal, particularmente un agente terapéutico para enfermedad arterial periférica.
MX2009013355A 2007-06-07 2008-06-06 Compuesto de piridona. MX2009013355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007151243 2007-06-07
PCT/JP2008/060417 WO2008149965A1 (ja) 2007-06-07 2008-06-06 ピリドン化合物

Publications (1)

Publication Number Publication Date
MX2009013355A true MX2009013355A (es) 2010-02-22

Family

ID=40093769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013355A MX2009013355A (es) 2007-06-07 2008-06-06 Compuesto de piridona.

Country Status (9)

Country Link
US (1) US20100179137A1 (es)
EP (1) EP2154130A4 (es)
JP (1) JPWO2008149965A1 (es)
KR (1) KR20100031725A (es)
CN (1) CN101679262A (es)
CA (1) CA2693552A1 (es)
MX (1) MX2009013355A (es)
TW (1) TW200911245A (es)
WO (1) WO2008149965A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066326A (zh) * 2008-06-17 2011-05-18 安斯泰来制药株式会社 吡啶酮化合物
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016098054A1 (en) * 2014-12-19 2016-06-23 Geistlich Pharma Ag Processes for preparing oxathiazin-like compounds
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322845A (en) 1991-10-02 1994-06-21 Sumitomo Chemical Company, Limited Acrylic acid derivatives, a fungicide containing them as an active ingredient, and intermediate compounds thereof
JPH05194398A (ja) * 1991-10-02 1993-08-03 Sumitomo Chem Co Ltd アクリル酸誘導体、その製造法およびそれを有効成分として含有する植物病害防除剤
WO2001087842A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CN1698362A (zh) * 2003-05-09 2005-11-16 松下电器产业株式会社 回放装置和分类回放方法
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
WO2005116010A1 (en) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
US7427614B2 (en) 2004-07-02 2008-09-23 Allergan, Inc. Prostaglandin analogs
US7994195B2 (en) 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006080323A1 (ja) 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
EP1912957A4 (en) 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
EP1912977A4 (en) 2005-08-03 2009-10-21 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
CN102066326A (zh) * 2008-06-17 2011-05-18 安斯泰来制药株式会社 吡啶酮化合物

Also Published As

Publication number Publication date
JPWO2008149965A1 (ja) 2010-08-26
US20100179137A1 (en) 2010-07-15
CN101679262A (zh) 2010-03-24
KR20100031725A (ko) 2010-03-24
WO2008149965A1 (ja) 2008-12-11
EP2154130A1 (en) 2010-02-17
TW200911245A (en) 2009-03-16
EP2154130A4 (en) 2011-09-07
CA2693552A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
MX2009013355A (es) Compuesto de piridona.
MX2010004503A (es) Compuesto de oxadiazolidinediona.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
DE602006012322D1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
MX2009001188A (es) Compuestos quimicos.
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
EP2361647A4 (en) DRUGS OUTPUT DEVICE
MX2012004848A (es) Compuestos heterociclicos triciclicos.
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
EA200970067A1 (ru) Агонисты ep2
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
GEP20135883B (en) Iminopyridine derivatives and usage thereof
MY163762A (en) Therapeutic agent for chronic renal failure
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
MX2009008176A (es) Derivados de tetrahidro-naftaleno sustituidos con heterociclos, su preparacion y su uso como medicamentos.
ATE474574T1 (de) Imidazoazephinonverbindungen
MX2010014231A (es) Compuestos de piridona.
TW200637817A (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal